Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sea & Ski ads

This article was originally published in The Tan Sheet

Executive Summary

Faulding Consumer launches $2 mil. national ad campaign to support 27-SKU sunscreen line recently reformulated with antioxidant astaxanthin. Print ads, slated to appear in upcoming issues of Family Circle, Child and Rosie, will feature children with elderly, sun-damaged faces and encourage mothers to "keep your kids from getting old before their time." Radio spots, May FSI drop will round out campaign, which coincides with Sea & Ski's April arrival on store shelves. Re-launch follows Faulding's acquisition of Sea & Ski in spring 2000 (1"The Tan Sheet" Oct. 15, 2001, p. 9)...

You may also be interested in...



Sea & Ski, Back On Sunscreen Scene, Slapped By Rival Who Never Left

Sea & Ski’s infrared protection claims read as a bold grab for competitive leverage after its disappearance from the market for more than a decade. But old rival Coppertone isn’t sitting idly by.

Sea & Ski Products Reformulated With Astaxanthin For Enhanced Anti-Aging

Faulding Consumer is re-launching the nearly 50 year-old Sea & Ski suncare line this spring with new formulas including the antioxidant astaxanthin for added anti-aging benefits.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel